I. EXECUTIVE SUMMARY

The SPORE Developmental Research Program (DRP) provides funding to support new and innovative pilot projects in lung cancer that have the potential to expand into full research projects in the future, including those of high risk-high reward nature. The DRP aims to foster collaborative research between Emory investigators and investigators at other institutions, and to enhance translational research in lung cancer by increasing the number of meritorious investigators working on lung cancer.

II. PROGRAM AIMS

Aim 1: To solicit research proposals by sending request for proposals (RFP) to all possible applicants at Emory University and other research and medical institutions throughout the state of Georgia;

Aim 2: To identify the most outstanding and novel proposals to fund through a clearly defined and well-established review process. Led by a DRP Committee, applications will be reviewed by a panel of leaders of all projects, cores/programs, and other researchers in relevant fields, following NIH review criteria; and

Aim 3: To monitor the progress of funded peer-reviewed pilot projects using a series of metrics, including the evolution of projects into major projects (e.g., R01s, full SPORE projects), publications, investigator career development etc.

III. PROGRAM DESCRIPTION

Winship Lung Cancer SPORE aims to pursue new and innovative research opportunities in the lung cancer field through the implementation of the Developmental Research Program (DRP). The DRP solicits, evaluates, and funds the most meritorious pilot projects, monitors progress twice annually, and promotes the most successful pilot projects into full projects funded by the SPORE and/or other sources. The goals of the DRP are to identify and support meritorious proposals that might expand into full research projects focused on lung cancer in the future, including those of high risk-high reward projects that might otherwise not be funded; to foster collaborative research between Emory investigators and investigators at other institutions; and to enhance translational research in lung cancer by increasing the number of investigators working in this field.